Physician profile
Jack E Saux
NPI 1528023843
$18,370.11
in general payments reported to CMS, 2019-2025
85 companies · $2,913 in 2025
The $2,913 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,301 · 2020: $916 · 2021: $1,255 · 2022: $2,745 · 2023: $3,139 · 2024: $3,101 · 2025: $2,913.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,052 · Education: $102.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,052.09 |
| Education | $101.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $1,483.55 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Merck Sharp & Dohme LLC | $1,261.70 | 2019-2025 | Keytruda, Lynparza, Reblozyl |
| Astrazeneca Pharmaceuticals Lp | $1,017.74 | 2019-2025 | Enhertu, Imfinzi, Lynparza |
| Pfizer INC. | $878.90 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $874.40 | 2019-2025 | |
| Celgene Corporation | $846.15 | 2019-2025 | Reblozyl, Pomalyst |
| Incyte Corporation | $762.65 | 2019-2025 | Jakafi, Monjuvi |
| Janssen Biotech, INC. | $708.61 | 2019-2025 | Darzalex, Rybrevant, Tecvayli |
| Daiichi Sankyo INC. | $561.96 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Takeda Pharmaceuticals U.S.A., INC. | $558.82 | 2019-2025 | Fruzaqla, Alunbrig, Ninlaro |
| Genzyme Corporation | $557.05 | 2019-2025 | |
| Exelixis INC. | $550.18 | 2019-2025 | Cabometyx |
| Genentech USA, INC. | $543.09 | 2019-2025 | Venclexta, Polivy, Itovebi |
| Gilead Sciences, INC. | $518.81 | 2021-2025 | Trodelvy |
| Astellas Pharma US INC | $494.31 | 2019-2025 | Padcev, Xtandi, Vyloy |
Show all 85 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Saux listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.